Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3 Randomized, Open-Label, Multicenter Clinical Study of CGT9486+Sunitinib vs. Sunitinib in Subjects With Locally Advanced, Unresectable, or Metastatic Gastrointestinal Stromal Tumors

Next Previous
Trial Profile

A Phase 3 Randomized, Open-Label, Multicenter Clinical Study of CGT9486+Sunitinib vs. Sunitinib in Subjects With Locally Advanced, Unresectable, or Metastatic Gastrointestinal Stromal Tumors

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 28 Apr 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bezuclastinib (Primary) ; Sunitinib (Primary)
  • Indications Gastrointestinal stromal tumours
  • Focus Pharmacokinetics; Registrational; Therapeutic Use
  • Acronyms PEAK
  • Sponsors Cogent Biosciences

Most Recent Events

  • 21 Apr 2026 According to a Cogent Biosciences media release, New Drug Application was submitted under the Real-Time Oncology Review (RTOR) program in March 2026.
  • 21 Apr 2026 According to a Cogent Biosciences media release, company announced that the results from the Phase 3 PEAK trial have been selected for oral presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, being held in Chicago, IL, May 29-June 2, 2026
  • 17 Feb 2026 According to a Cogent Biosciences media release, complete submission of PEAK NDA anticipated in April 2026 for bezuclastinib in patients with GIST who have received prior treatment with imatinib.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top